EICHORCondition: Urinary Bladder Neoplasms · Sponsor: Queen Mary University of London
This is an adaptive, open-label, randomised phase II trial that aims to evaluate the impact of 3 vs 6 cycles of first-line platinum-based chemotherapy followed by maintenance avelumab in the quality of life of patients with locally advanced or metastatic urothelial cancer. Initially, 224 eligible and evaluable patients (112 in each arm) will receive 3 cycles vs 6 cycles of 3-weekly gemcitabine plus cisplatin/carboplatin, followed by 2-weekly maintenance avelumab until disease progression or intolerable toxicities. Avelumab treatment will be given up to a maximum of 2 years from the end of chemotherapy.
This description comes directly from the study's public registry record.
DISCUS Trial Coordinator · bci-discus@qmul.ac.uk · Bci-discus@qmul.ac.uk
Thomas Powles · thomas.powles1@nhs.net
Always discuss trial participation with your own doctor first.
| Unicancer | Paris, France | Recruiting |
| Adknoma | Madrid, Spain | Enrolling By Invitation |
| Barts Health NHS Trust | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06892860